<Anchor> The
FDA of the US Food and Drug Administration has announced that it is safe and effective for Johnson & Johnson's corona vaccine.
It is expected to be approved soon, but there are no cases of death or allergic reactions after being vaccinated, and storage is reported to be easy.
This is Kim Yoon-soo, correspondent in Washington.
<Reporter> The
FDA of the US Food and Drug Administration said that Johnson & Johnson's COVID-19 vaccine phase 3 clinical trial showed 72% in the US and 64% in South Africa.
The preventive effect is lower than that of Pfizer and Moder or vaccines, which are more than 90%, but exceeds the FDA's lowest limit of 50%.
In particular, it differs from previously approved vaccines in that clinical trials were conducted after the mutant virus spread.
The effectiveness of preventing severe COVID-19 has risen significantly to 86% in the US and 82% in South Africa.
No cases of vaccinating deaths or serious allergic reactions have been reported.
[Gupta/CNN medical reporter: What is the goal of the vaccine?
It prevents severe infections, hospitalization and death.
In this regard, this vaccine seems to be quite effective.] The
US FDA is planning to hold an advisory meeting on the 26th to discuss whether to recommend the use of the vaccine.
Johnson & Johnson plans to supply 100 million servings to the U.S. by June, and 1 billion servings to the world by the end of this year when emergency use is approved.
[Giants/U.S. White House Corona 19 Coordinator: If urgent use is approved, it is expected that 3-4 million doses of Johnson & Johnson vaccine will be allocated by next week.]
Unlike existing vaccines, this vaccine only needs to be given once. , There is an expectation that it can be a'game changer' as it can be stored for three months at a refrigerated temperature.